LEO Pharma's Enstilar gets FDA approval for topical treatment of plaque psoriasis
LEO Pharma Inc., a wholly owned U.S. subsidiary of LEO Pharma A/S, announced today that Enstilar has been approved by the U.S. Food and Drug Administration for the topical treatment of plaque psoriasis in adults...